Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Roboz

Showing results (141-150 of 276) with videos related to

Pageof 28
Sort By:
Leukemia Research|March 14, 2024
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND studyB Douglas Smith, Tim H Brümmendorf, Gail J Roboz, et al.
Cold Spring Harbor Perspectives in Biology|April 3, 2019
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and BeyondTony Taldone, Tai Wang, Anna Rodina, et al.
Leukemia & Lymphoma|October 25, 2016
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)Amy E DeZern, Amer M Zeidan, John Barnard, et al.
Leukemia Research|March 11, 2021
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survivalJacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Leukemia Research|April 26, 2021
Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]Jacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Leukemia & Lymphoma|January 15, 2025
High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemiaAlison K Heilbronner, Olivia Blumberg, Alexandra Krez, et al.
The Lancet. Haematology|December 5, 2024
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemiaIbrahim Aldoss, Gail J Roboz, Renato Bassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Haematologica|May 5, 2018
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemiaGail J Roboz, Ellen K Ritchie, Yulia Dault, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz, Francis J Giles, Ellen K Ritchie, et al.
Pageof 28

Showing results (141-150 of 276) with videos related to

Sort By:
Pageof 28
Leukemia Research|March 14, 2024
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND studyB Douglas Smith, Tim H Brümmendorf, Gail J Roboz, et al.
Cold Spring Harbor Perspectives in Biology|April 3, 2019
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and BeyondTony Taldone, Tai Wang, Anna Rodina, et al.
Leukemia & Lymphoma|October 25, 2016
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)Amy E DeZern, Amer M Zeidan, John Barnard, et al.
Leukemia Research|March 11, 2021
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survivalJacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Leukemia Research|April 26, 2021
Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]Jacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Leukemia & Lymphoma|January 15, 2025
High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemiaAlison K Heilbronner, Olivia Blumberg, Alexandra Krez, et al.
The Lancet. Haematology|December 5, 2024
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemiaIbrahim Aldoss, Gail J Roboz, Renato Bassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Haematologica|May 5, 2018
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemiaGail J Roboz, Ellen K Ritchie, Yulia Dault, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz, Francis J Giles, Ellen K Ritchie, et al.
Pageof 28